Start the conversation
|Penny Stocks||Current Share Price||Dec. 11-15 Gain (as of Dec. 15)|
|Proteostasis Therapeutics Inc. (Nasdaq: PTI)||$4.99||97.23%|
|Shiftpixy Inc. (Nasdaq: PIXY)||$3.90||83.96%|
|One Horizon Group (Nasdaq: OHGI)||$1.87||81.55%|
|Seven Stars Cloud Group Inc. (Nasdaq: SSC)||$4.20||66.07%|
|Yield10 Bioscience Inc. (Nasdaq: YTEN)||$3.20||56.10%|
|Sunesis Pharmaceuticals Inc. (Nasdaq: SNSS)||$3.36||54.13%|
|Arcimoto Inc (Nasdaq: FUV)||$4.46||51.19%|
|Concordia International Corp. (Nasdaq: CXRX)||$0.77||47.91%|
|Neptune Technologies & Bioresources Inc. (Nasdaq: NEPT)||$2.09||46.15%|
|Medallion Financial Corp. (Nasdaq: MFIN)||$4.06||45%|
Proteostasis is a Boston-based pharmaceutical company developing treatments for diseases caused by dysfunctional protein processing, such as cystic fibrosis.
Last Tuesday (Dec. 12), the company announced positive clinical trial results in all three of its drugs in development.
As a result, its share price shot up from $2.52 to $6.37 on Tuesday. The stock pulled back to $4.99 by the end of the week, for a total gain of 97.23%.
While PTI's 97% gain was impressive, we're recommending a different stock to our readers today. The company we'll show you today has beaten analyst earnings expectations by an average of 40.5% in the last four quarters, and we expect more earnings growth going forward.
But before we show you our pick, here are the top 10 penny stocks to watch this week…
FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, it's completely free…
While the returns these penny stocks delivered in just five trading sessions look attractive, they come with huge risk.
You see, most penny stocks are speculative investments and can be extremely volatile. In this case, after climbing from $2.52 to $6.37 on Tuesday, shares fell to $4.99 by the end of the week. If you had bought at the top, you'd be looking at losses of 21.66%.
Our Money Morning experts are more interested in finding companies that will increase in value over the long term.
That's where Money Morning Small-Cap Specialist Sid Riggs comes in.
He's an expert at bringing readers profit opportunities with massive potential at an affordable price. Consider his pick from December 2013, Neurocrine Biosciences Inc. (Nasdaq: NBIX). NBIX was trading for just $9 per share when Sid recommended it, and now it has surged 686.33%, to $70.77.
Today, Sid recommends a medical device company whose products are used to test for HIV as well as treat benign skin lesions through freezing.
It's the first company to sell an at-home HIV testing kit. But that's only part of the story.
Here's why this stock could take off next year…